Skip to main content
Alligator Bioscience logo

Alligator Bioscience — Investor Relations & Filings

Ticker · ATORX ISIN · SE0024173637 LEI · 549300E15VI0MB7LXV19 ST Manufacturing
Open in API
Filings indexed 610 across all filing types
Latest filing 2017-11-13 AGM Information
Country SE Sweden
Listing ST ATORX

About Alligator Bioscience

https://alligatorbioscience.se/en/

Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.

Recent filings

Filing Released Lang Actions
Nomination Committee appointed in respect of AGM 2018 in Alligator Bioscience AB
AGM Information Classification · 1% confidence The document explicitly discusses the appointment of the Nomination Committee in preparation for the Annual General Meeting (AGM) scheduled for April 26, 2018. It details the composition of the committee, the process for submitting proposals, and the role of the committee leading up to the AGM. This content directly relates to the preparatory materials and governance surrounding the AGM, fitting the definition of 'AGM Information' (AGM-R). It is not a full report (10-K, IR), a management change announcement (MANG), or a proxy solicitation (PSI), but rather specific information about the AGM process itself.
2017-11-13 English
Valberedning utsedd inför årsstämma 2018 i Alligator Bioscience AB
AGM Information Classification · 1% confidence The document is titled "Valberedning utsedd inför årsstämma 2018 i Alligator Bioscience AB" (Nominations Committee appointed ahead of the 2018 Annual General Meeting in Alligator Bioscience AB). It details the composition and mandate of the Nomination Committee responsible for proposing candidates and procedures for the upcoming Annual General Meeting (AGM). This content directly relates to the governance and preparation for the AGM, specifically concerning the election of board members and related remuneration/procedures. This falls under the scope of AGM-related materials, specifically the appointment of the committee that prepares for the AGM, which is closely related to AGM Information (AGM-R) or potentially Governance Information (CGR). However, since the core subject is the *appointment* of the committee *for* the AGM, AGM-R is the most precise fit among the provided options, as it covers AGM presentations and materials, and this announcement sets the stage for the AGM.
2017-11-13 Swedish
Resultaten från Alligator Biosciences kliniska fas I-studie stödjer fortsatt klinisk utveckling av ADC-1013
Regulatory Filings Classification · 1% confidence The document is a press release from Alligator Bioscience dated November 7, 2017, announcing positive results from a Phase I clinical trial for their drug candidate ADC-1013. It details safety, tolerability, and plans to present the data at an upcoming conference (SITC). This type of announcement, which releases key financial/operational results for a period (even if it's trial data rather than quarterly revenue), is typically classified as an Earnings Release (ER) if it were quarterly results, or a Regulatory Filing (RNS) if it were a general update. However, since it is a specific announcement of operational results (clinical trial data) that is not a full financial report (10-K, IR) or a management discussion (MDA), and it is a direct announcement of key operational progress, it fits best under the general category for significant operational updates that aren't explicitly defined elsewhere. Given the context of a biotech company announcing trial results, this is a significant operational update. It is not a Call Transcript (CT), Investor Presentation (IP), or a formal Audit Report (AR). It is a direct announcement of results, making 'ER' (Earnings Release, used broadly for period results announcements) or 'RNS' (Regulatory Filings/General Announcement) candidates. Since it is a specific, material operational update announcing trial success, and not just a notice that a report is coming (RPA), 'RNS' is the most appropriate fallback for a material, non-standardized operational announcement in this context, although 'ER' is often used for any period result announcement. Given the specific nature of clinical trial results, which are material operational milestones, and lacking a specific 'Clinical Trial Result' code, RNS serves as the best fit for a material regulatory/operational announcement not covered by the other specific codes.
2017-11-07 Swedish
Results from Alligator Bioscience’s clinical phase I study support further clinical development of ADC-1013
Regulatory Filings Classification · 1% confidence The document is a press release dated November 7, 2017, announcing positive results from a clinical phase I study of the drug candidate ADC-1013. It details safety, tolerability, and preliminary efficacy data, and mentions that the full data will be presented at an upcoming scientific meeting (SITC). This content structure—announcing key clinical trial results and upcoming presentation details—is characteristic of an Earnings Release (ER) or a general press release related to operational/clinical progress. Since it is not a comprehensive periodic financial report (10-K or IR), nor a transcript (CT), nor a formal management discussion (MDA), the most appropriate classification for an initial announcement of key operational/clinical results is 'Earnings Release' (ER), as these announcements often coincide with or precede quarterly reporting periods and serve to inform investors of material progress. Given the context of a biotech company, clinical trial updates are material news releases.
2017-11-07 English
Interim / Quarterly Report 2017
Interim / Quarterly Report Classification · 1% confidence The document is titled 'DELÅRSRAPPORT' (Interim Report) for the period January-September 2017. It contains comprehensive financial statements, including income statements, cash flow, and balance sheet summaries, as well as detailed management commentary on business operations, clinical trials, and research collaborations. It is not a short announcement or a certification, but a full interim financial report. 9M 2017
2017-10-25 Swedish
Interim / Quarterly Report 2017
Interim / Quarterly Report Classification · 1% confidence The document is titled 'INTERIM REPORT JANUARY-SEPTEMBER 2017' and contains comprehensive financial statements, including a 'Financial summary (Group)' table with comparative data for the period, as well as detailed management commentary on operations, clinical trials, and business strategy. It is clearly a quarterly/interim financial report, not an announcement of a report or a simple regulatory filing. 9M 2017
2017-10-25 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.